Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

NCT05786521 · Completed

Last updated 2026-05-28

This clinical trial is testing how GLP1 receptor agonists affect muscle mass, body fat, and aging-related markers in older adults with diabetes, prediabetes, or obesity.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 20 people

Who can join Ages 65–90 · all sexes

Timeline Started 2023-04 · est. completion 2024-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05786521 ↗

Description as written by the study sponsor.

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Treatments tested

Semaglutide Injectable Product also known as Semaglutide and Lifestyle Counseling Drug

Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
Lifestyle Counseling Behavioral

Lifestyle Counseling will be provided throughout study intervention

Main thing measured	Lean Body Mass Change
Sponsor	The University of Texas Health Science Center at San Antonio
Conditions studied	Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05786521 ↗